PYTX 004
Alternative Names: PYTX-004Latest Information Update: 01 Feb 2024
At a glance
- Originator Papyrus Therapeutics
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Gastric cancer; Ovarian cancer
Most Recent Events
- 23 Jan 2024 Papyrus Therapeutics has patent protection for platform of novel tumor suppressor therapies in USA
- 05 Jun 2023 Papyrus Therapeutics receives Notice of Allowance for platform of novel tumor suppressor therapies in USA
- 06 Apr 2023 Papyrus Therapeutics plans to submit IND application to the US FDA for Cancer in Q1 2025 (Papyrus Therapeutics Pipeline, April 2023)